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Background: Cold ischemia time (CIT) has been associated to heart transplantation (HT) prognosis. However, 
there is still uncertainty regarding the CIT cutoff value that might have relevant clinical implications. 
 
Methods: We analyzed all adults that received a first HT during the period 2008–2018. CITwas defined as the 
time between the cross-clamp of the donor aorta and the reperfusion of the heart. Primary outcome was 1-
month mortality. 
 
Results: We included 2629 patients, mean agewas 53.3±12.1 years and 655 (24.9%) were female. Mean CIT 
was 202 ± 67 min (minimum 20 min, maximum 600 min). One-month mortality per CIT quartile was 9, 12, 
13, and 19%. One-year mortality per CIT quartile was 16, 19, 21, and 28%. CIT was an independent predictor 
of 1-month mortality, but only in the last quartile of CIT >246 min (odds ratio 2.1, 95% confidence interval 
1.49–3.08, p < .001). We found no relevant differences in CIT during the study period. However, the impact 
of CIT in 1-month and 1-year mortality decreased with time (p value for the distribution of ischemic time by 
year 0.01), particularly during the last 5 years.  
 
Conclusions: Although the impact of CIT in HT prognosis seems to be decreasing in the last years, CIT in the 
last quartile (> 246 min) is associated with 1-month and 1-year mortality. Our findings suggest the need to 
limit HT with CIT N> 246 min or to use different myocardial preservation systems if the expected CIT is> 4 
h. 
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1. Introduction 
Heart transplantation (HT) is the treatment of choice for carefully selected patients with 
advanced or end-stage heart failure [1], with a median survival around 12 years. Among the 
different factors that may influence the prognosis of HT [2], cold ischemia time (CIT) has been 
associated with primary graft failure and mortality [3] and is one of the most important risk factors 
for early graft dysfunction [4]. However, there is still uncertainty regarding the CIT cutoff value 
that might have relevant clinical implications. The recent changes in HT have included an increase 
in donors and recipients age, in the rate of emergent transplantation, and, according to some data, 
of CIT [5]. Yet, this change has not been associated with higher mortality [6]. Although different 
strategies have been developed in order to expand the pool of donors, including donation-after-
circulatory-death and TransMedics® Organ Care System [7] the vast majority of HT are done with 
hearts preserved in cold systems [8]. 
 
The aim of our study was to examine, in a large National consecutive HT registry, the trend of 
CIT in the last decade, as well as its influence on 30-day and 1-year. 
 
2. Methods 
2.1. Population and data collection 
Our data come from the Spanish Heart Transplantation Registry, a prospective database 
promoted by the Working Group in Heart Failure of the Spanish Society of Cardiology that 
contains detailed clinical information about all HT performed in our nation. The registry is 
updated in a yearly basis with data supplied by all HT centers of the country. This database has 
been described elsewhere [6]. For the purpose of this study, data regarding CIT, baseline recipient 
characteristics, donor, surgical procedure, and survival were obtained from the database. 
 
2.2. Study population 
This was a retrospective analysis involving recipients from 17 participating centers who 
fulfilled the following inclusion criteria: 1) Recipient of a first isolated HT between January 2008 
and November 2018; 2) Age at transplant >16 years; 3) Information of CIT available. CIT was 
defined as the time between the cross-clamp of the donor aorta and the reperfusion of the heart. 
The Spanish system tries to minimize the distance between donor and recipient but also prioritizes 
emergencies. First level emergencies have National priority. 
 
The study was conducted according to the guidelines of the Declaration of Helsinki and was 
approved by the Ethics Committees of all the participating centers. 
 
2.3. Statistical analysis 
Data are presented as median with interquartile range (IQR) for continuous variables and 
frequency with percentage for categorical variables. Comparison between groups was conducted 
by use of Mann-Whitney U analysis. Categorical variables were compared by using χ2 or Fisher 
exact tests. Association between variables was assessed by using linear regression analysis and 
correlation by means of the non-parametric Spearman rho. CIT quartiles were used to assess the 
influence of CIT in prognosis. The primary outcome was 1-month mortality. One-year survival 
was also analyzed as secondary outcome. Univariate relations between variables and the primary 
endpoint were assessed by logistic regression analysis. Multiple logistic regression model was 
built using stepwise backward model after excluding those with >10% of missing data. Multiple 
logistic was repeated including those variables with imputation of missing data without relevant 
changes (data not shown). The logrank test was used to compare survival among the 4 CIT 
quartiles. Statistical analysis was performed using the Stata 13.0 package (StataCorp LP, Tx). 
 
3. Results 
A total of 2977 HT were included in the registry during the study period but 348 were excluded 
from this study (232 age < 16 years, 57 combined transplantation, 46 retransplantation, and 13 CIT 
unavailable). The final population of 2629 had a mean age of 53.3 ± 12.1 years and 655 women 
(24.9%). Mean CIT was 202 ± 67 min (minimum 20 min, maximum 600 min). Table 1 shows 
characteristics according to CIT quartile (Table 1). Urgent HT, mechanical ventilation and 
ventricular assist device were more common in the upper CIT quartiles. 
  
Table 1. Baseline characteristics according to cold ischemia time (CIT) quartile. 
Characteristic Ischemic time quartiles p-value 
≤ 159 min 160–210 min 211–246 min > 246 min  
Mean ± SD or 
no. (%) (n = 664) 
Mean ± SD or 
no. (%) (n = 724) 
Mean ± SD or 
no. (%) (n = 591) 
Mean ± SD or 
no. (%) (n = 650) 
 
A) Recipients 
Age. mean ± SD 53.8 ± 11.8 53.7 ± 11.2 52.8 ± 12.3 52.6 ± 12.4 0.326 
Sex (males) 503 (75.8) 552(76.2) 425(71.9) 494(76.0) 0.632 
BMI. mean ± SD 25.5 ± 3.91 25.5 ± 4.13 25.4 ± 3.92 25.8 ± 4.18 0.224 
Cardiomyopathy      
 Nonischemic dilated cardiomyopathy 268(40.4) 280(38.7) 234(39.6) 226(34.8) 0.558 
 Ischemic dilated cardiomyopathy 181(27.3) 214(29.6) 168(28.4) 226(34.8)  
 Valvular 39(5.9) 36(5.0) 41(6.9) 44(6.8)  
 Others 176(26.5) 194(26.8) 148(25.0) 154(23.7)  
PVR (UW). mean ± SD 2.2 ± 1.2 2.3 ± 1.5 2.3 ± 1.7 2.1 ± 1.3 0.130 
Creatinine >2 mg/dl 30(4.5) 39(5.4) 23(3.9) 36(5.6) 0.667 
Bilirubin >2 mg/dl 116(18.9) 109(16.4) 89(16.4) 103(17.6) 0.541 
Diabetes mellitus 135(20.5) 149(20.7) 126(21.4) 146(22.7) 0.308 
COPD moderate-severe 68(11.2) 81(12.0) 59(10.4) 57(8.9) 0.130 
Previous infection 69(10.4) 93(12.9) 93(15.7) 124(19.2) <0.001 
Previous thoracic surgery 142(21.5) 187(25.9) 181(31.0) 226(34.9) <0.001 
Urgent transplant 186(28.0) 271(37.4) 287(48.6) 311(47.9) <0.001 
Mechanical ventilation prior  to transplant 63(9.6) 77(10.7) 107(18.1) 138(21.5) <0.001 
VAD prior to HT      
 No 490(74.4) 480(67.0) 337(57.2) 368(57.0) <0.001 
 IABP 62(9.4) 89(12.4) 89(15.1) 89(14.7)  
 ECMO 47(7.1) 52(7.3) 61(10.4) 67(10.4)  
 Continuous flow-VAD 47(7.1) 79(11.0) 74(12.6) 82(12.7)  
 Pulsatile flow-VAD 13(2.0) 16(2.2) 28(4.8) 34(5.3)  
 
B) Donor 
Age. mean ± SD 43.8 ± 12.5 43.2 ± 12.5 43.4 ± 12.6 42.1 ± 12.7 0.085 
Sex (males) 408(61.54) 447(61.7) 369(62.5) 440(67.7) 0.023 
Female donor/male recipient 163(24.6) 169(23.3) 117(19.8) 125(19.2) 0.007 
Weight. mean ± SD 77.1 ± 14.4 76.3 ± 13.8 76.4 ± 13.3 77.1 ± 14.3 0.581 
Weight recipient/donor >1.20 57(8.7) 72(10.0) 41(7.0) 71(10.9) 0.453 
Weight recipient/donor <0.8 123(18.7) 118(16.3) 106(18.0) 112(17.2) 0.683 
Cause of death      
 Cerebrovascular 395(59.6) 405(56.1) 336(57.1) 366(56.8) 0.265 
B) Donor 
 Traumatism 167(25.2) 205(28.4) 150(25.5) 165(25.6)  
 Others 101(15.2) 112(15.5) 103(17.5) 113(17.6)  
 
C) Complications and mortality 
Primary graft failure 125(19.2) 159(22.3) 128(22.5) 184(29.5) <0.001 
ICU stay length 9.7 ± 11.5 10.6 ± 13 12.4 ± 15.1 11.9 ± 16.2 <0.001 
CAV 56(8.4) 74(10.2) 48(8.1) 49(7.5) 0.337 
Infection 231(38.8) 259(39.4) 206(40.5) 189(33.9) 0.148 
Hypertension 232(40.0) 278(44.7) 200(39.7) 238(43.8) 0.495 
Diabetes      
 No 370(66.5) 411(66.4) 332(66.7) 357(66.9) 0.769 
 Diet 10(1.8) 14(2.3) 17(3.4) 15(2.8)  
 Oral antidiabetics 47(8.3) 56(9.1) 45(9.0) 40(7.5)  
 Insulin 134(23.5) 138(22.3) 104(20.9) 122(22.9)  
Neurologic disease 60(10.4) 91(14.6) 87(17.4) 104(19.2) <0.001 
Renal replacement therapy 38(6.7) 50(8.1) 42(8.4) 56(10.4) 0.030 
Permanent pacemaker 31(5.6) 31(5.2) 22(4.6) 15(2.9) 0.034 
1-month mortality 58(8.7) 86(11.9) 74(12.5) 121(18.6) <0.001 
1-year mortality 104(15.7) 140(19.3) 125(21.2) 179(27.5) <0.001 
 
BMI: body mass index. PVR: pulmonary vascular resistance. COPD: chronic obstructive pulmonary disease. VAD: 
ventricular assistance device. IABP: Intraaortic balloon pump. ECMO: extracorporeal membrane oxygenation. 
ICU: Intensive care unit. CAV: Cardiac Allograft Vasculopathy. 
The rate of primary graft failure increased with CIT quartile, and was particularly high in the 
last quartile (19% - 22% - 23% - 30%). This was also the case with 1-month (9% - 12% - 13% - 
19%) and 1-year (16% - 19% - 21% - 28%) mortality. Table 2 shows univariate and multivariate 
logistic regression analysis for 1-month and 1-year mortality (Table 2). CIT was an independent 
predictor of 1-month mortality (odds ratio [OR] per min 1.00, 95% confidence interval [CI] 1.00–
1.01, p < .001). CIT was also an independent predictor of 1-year mortality (OR per min 1.00, 95% 
CI 1.00–1.01, p < .001). Of note, in both cases, the independent influence of CIT in the prognosis 
was only seen in the last quartile. shows the Kaplan-Meier curves according to CIT quartile. 
  
Table 2. Univariate and multivariate logistic regression analysis for A) 1-month mortality and B) 1-year mortality 
 OR (95% CI) p-value % missing 
A    
Ischemic time 1.00 (1.00–1.01) <0.01 0.49 
Recipient data    
Age 1.00 (0.99–1.01) 0.565 0.00 
Sex (Female) 1.18 (0.92–1.52) 0.197 0.00 
BMI 1.00 (0.98–1.03) 0.750 0.11 
Cardiomyopathy    
 Nonischemic dilated cardiomyopathy    
 Ischemic dilated cardiomyopathy 1.12 (0.85–1.49) 0.423 0.00 
 Valvular 1.49 (0.94–2.35) 0.087  
 Others 1.22 (0.92–1.63) 0.172  
Kidney failure 1.44 (1.12–1.86) <0.01 3.10 
Creatinine 1.12 (0.97–1.31) 0.133 0.45 
Bilirubin >2 mg/dl 1.74 (1.31–2.30) <0.01 8.52 
PVR 1.08 (1.00–1.17) 0.046 16.24 
Previous infection 1.81 (1.36–2.40) <0.01 0.23 
Diabetes Mellitus 0.97 (0.73–1.28) 0.824 0.64 
COPD moderate-severe 1.10 (0.76–1.60) 0.598 5.19 
Mechanical ventilation 2.50 (1.91–3.27) <0.01 0.79 
VAD prior to HT 1.38 (1.10–1.74) <0.01 0.72 
Previous thoracic surgery 1.41 (1.11–1.80) <0.01 0.64 
Emergency level (emergent/elective) 0.70 (0.56–0.88) <0.01 0.00 
Donor data    
Age 1.01 (1.00–1.02) 0.175 0.08 
Sex (Female) 1.00 (0.79–1.26) 0.967 0.08 
Cause of death    
 Cerebrovascular    
 Traumatism 1.03 (0.79–1.34) 0.813 0.45 
 Others 0.85 80.61–1.18) 0.332  
 
 Multivariate OR (95% CI) p-value 
1-month mortality 
Cold ischemia time 
1 - ≤159 min 1  
2–160-210 min 1.37 (0.94–1.99) 0.11 
3–211-246 min 1.33 (0.90–1.98) 0.15 
4 - >246 min 2.14 (1.49–3.08) <0.01 
 Multivariate OR (95% CI) p-value 
1-month mortality 
Transplant year 0.94 (0.90–0.98) <0.01 
Kidney failure 1.42 (1.07–1.88) 0.01 
Bilirubin ≥2 mg/dl 1.55 (1.15–2.08) <0.01 
Mechanical ventilation 2.24 (1.67–3.01) <0.01 
Previous thoracic surgery 1.37 (1.05–1.78) 0.02 
 
 OR (95% CI) p-value % missing 
B 
Ischemic time 1.00 (1.00–1.01) <0.01 0.49 
Recipient data    
Age 1.01 (1.00–1.02) <0.01 0.00 
Sex (Female) 1.17 (0.95–1.45) 0.142 0.00 
BMI 1.02 (0.99–1.04) 0.129 0.11 
Cardiomyopathy    
 Nonischemic dilated cardiomyopathy    
 Ischemic dilated cardiomyopathy 1.08 (0.86–1.36) 0.524 0.00 
 Valvular 1.27 (0.86–1.88) 0.227  
 Others 1.12 (0.88–1.43) 0.345  
Kidney failure 1.62 (1.31–2.00) <0.01 3.10 
Creatinine 1.32 (1.12–1.55) <0.01 0.45 
Bilirubin >2 mg/dl 1.69 (1.33–2.14) <0.01 8.52 
PVR 1.05 (0.98–1.13) 0.155 16.24 
Previous infection 1.82 (1.43–2.32) <0.01 0.23 
Diabetes Mellitus 1.10 (0.88–1.38) 0.406 0.64 
COPD moderate-severe 1.15 (0.85–1.55) 0.374 5.19 
Mechanical ventilation 2.39 (1.89–3.02) <0.01 0.79 
VAD prior to HT 1.50 (1.24–1.82) <0.01 0.72 
Previous thoracic surgery 1.31 (1.07–1.61) <0.01 0.64 
Emergency level (emergent/elective) 0.65 (0.65–0.78) <0.01 0.00 
Donor data    
Age 1.00 (1.00–1.01) 0.220 0.08 
Sex (Female) 0.97 (0.80–1.18) 0.764 0.08 
Cause of death    
 1-Cerebrovascular    
 2-Traumatism 1.01 (0.81–1.26) 0.937 0.45 
 3- Others 0.83 (0.63–1.09) 0.186  
 
 Multivariate OR (95% CI) p-value 
1-year mortality   
Cold ischemia time   
1 - ≤159 min 1  
2–160-210 min 1.25 (0.93–1.67) 0.14 
3–211-246 min 1.29 (0.94–1.76) 0.11 
4 - >246 min 1.83 (1.36–2.45) <0.01 
Transplant year 0.95 (0.92–0.98) <0.01 
Recipient age 1.01 (1.00–1.02) 0.02 
Kidney failure 1.57 (1.25–1.98) <0.01 
Bilirubin ≥2 mg/dl 1.55 (1.20–2.00) <0.01 
Mechanical ventilation 2.21 (1.71–2.86) <0.01 
Previous thoracic surgery 1.31 (1.05–1.64) 0.02 
Kidney failure: creatinine >2 mg/dl. PVR: Pulmonary Vascular Resistance. VAD: Ventricular assist device (includes 
ECMO). OR: odds ratio. CI: confidence interval. 
 
We found no relevant differences in CIT during the study period (Fig. 2). However, the impact 
of CIT in 1-month and 1-year mortality decreased with time (p value for Kruskal-Wallis test to the 











Fig. 2. Cold ischemia time during each year of the study period. 
4. Discussion 
Our main finding is that, although the impact of CIT in HT prognosis seems to be decreasing in 
the last years, CIT in the last quartile (>246 min) is associated with 1-month and 1-year mortality. 
 
The association of CIT with HT prognosis has been previously described [[9], [10], [11], [12]]. 
However, there still is uncertainty regarding the prognostic effect of CIT and of the cutoff value 
that might have relevant clinical implications. Some studies have reported no differences in 
survival even with prolonged CIT [13,14] or have described different cutoffs [15,16]. 
 
Our data suggest that we should be concern when ischemic time is longer than 4 h. Del Rizzo 
et al. also found a clear relation of CIT >4 h with mortality, but only in donors >50 years [17]. 
Their small sample size (only 372) might have been underpowered to detect the prognostic 
influence with younger donors. In fact, even in children, CIT >3.5 h implies an increased risk of 
graft loss [18]. Reich et al. studied the influence of donor age in CIT prognostic effect [12], under 
the hypothesis that older donors could be more susceptible to prolonged CIT but found no 
significant differences. We were also unable to find a specific effect of donor age in CIT 
prognostic effect. 
 
Two previous single-center studies were unable to find an influence of CIT in the prognosis of 
HT [13,14]. The first was focused on long-term survival [13] and compared 4 CIT groups (<150, 
150–200, 200–250, >250 min), of note only 80 had CIT >250 min and this low number probably 
limited the power to detect CIT prognostic influence. In fact, the only independent predictor the 
authors were able to find was recipient female sex. The second study [14] compared 46 HT with 
CIT >300 min with 46 case-matched controls. Although 30-day mortality in patients with CIT > 
300 min was twice that in controls, both groups had a very low 30-day mortality [4.3% vs. 2.1%], 
compared with our 12.9%. In fact, in that study, only 3 patients died in the 30-day period. One of 
the strengths of our study is the large number of patients in the upper quartile [650]. Moreover, 
previous thoracic surgery, that in our study was an independent predictor of mortality, is also 
associated to longer CIT [19]. 
 
Although some authors have described an increase in CIT during a 10-year period [20], our 
data do not support this increase. However, the peculiarities of the Spanish National Transplant 
System [21] might protect our centers from such increase. In any case, our data suggest that the 
influence of CIT in prognosis is decreasing, as can be seen in the yellow lines depicted in the 
Supplementary Figure. The reasons why the effect of prolonged CIT might be reduced in the most 
recent era are unknown. The increasing use of mechanical circulatory support might make 
recipients in better overall condition at the time of transplant. Also, the better selection of donors, 
including, when possible, avoiding sex mismatch in male recipients [22,23] might play a role. 
 
Patients in the lower CIT quartile were supported by a ventricular assist device less often than 
patients in the upper quartile. However, in our registry, ventricular assist device prior to HT was 
not a risk factor for mortality at 1-month or 1-year after HT, a finding previously described 
[24,25]. In any case, it is clear that patients with prolonged CIT had a greater risk profile. In fact, 
compared to recipients with shorter CIT, they had more frequently variables that might be 
associated with a poor prognosis. These variables include not only circulatory support but also 
prior infection, previous thoracic surgery, urgent transplant, and mechanical ventilation. All these 
variables were included in the multivariable analysis. However, it is conceivable that multivariate 
analysis was not able to correct completely all the differences regarding the risk profile of the four 
CIT quartiles. 
 
Our study has more limitations. Missing data could have influenced our results. Although in 
most variables the rate of missing values was extremely low, in some of then, as pulmonary 
vascular resistance, was higher than 10%. The data came from Spain, with specific patient 
characteristics and, even more so, logistics, criteria for distribution, and distance from donor to 
recipient centers. So, the extrapolation of our findings to other health systems should be done with 
caution. In any case the homogeneity of our National transplant system is also an advantage as 
decreases the possibility of bias. For instance, in Spain HT after TransMedics ® Organ Care 
System or donation-after-circulatory-death have not been performed. 
 
In conclusion, although the impact of CIT in HT prognosis seems to be decreasing in the last 
years, CIT in the last quartile (>246 min) is associated with 1-month and 1-year mortality. Our 
findings suggest the need to limit HT with CIT > 246 min or to use different myocardial 
























Supplementary Figure 1. Thirty-day and 1-year mortality according to cold ischemia time quartile during 
each year of the study period. 
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